Cargando…
A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991281/ http://dx.doi.org/10.1186/2051-1426-1-S1-P127 |
| _version_ | 1782312407936270336 |
|---|---|
| author | Burris, Howard Ansell, Stephen Neumanitis, John Weiss, Geoffrey Sikic, Branimir Northfelt, Donald Pilja, Lana Davis, Thomas Yellin, Michael Keler, Tibor Bullock, Timothy |
| author_facet | Burris, Howard Ansell, Stephen Neumanitis, John Weiss, Geoffrey Sikic, Branimir Northfelt, Donald Pilja, Lana Davis, Thomas Yellin, Michael Keler, Tibor Bullock, Timothy |
| author_sort | Burris, Howard |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3991281 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-39912812014-05-05 A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors Burris, Howard Ansell, Stephen Neumanitis, John Weiss, Geoffrey Sikic, Branimir Northfelt, Donald Pilja, Lana Davis, Thomas Yellin, Michael Keler, Tibor Bullock, Timothy J Immunother Cancer Poster Presentation BioMed Central 2013-11-07 /pmc/articles/PMC3991281/ http://dx.doi.org/10.1186/2051-1426-1-S1-P127 Text en Copyright © 2013 Burris et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Poster Presentation Burris, Howard Ansell, Stephen Neumanitis, John Weiss, Geoffrey Sikic, Branimir Northfelt, Donald Pilja, Lana Davis, Thomas Yellin, Michael Keler, Tibor Bullock, Timothy A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors |
| title | A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors |
| title_full | A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors |
| title_fullStr | A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors |
| title_full_unstemmed | A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors |
| title_short | A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors |
| title_sort | phase i study of an agonist anti-cd27 human antibody (cdx-1127) in patients with advanced hematologic malignancies or solid tumors |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991281/ http://dx.doi.org/10.1186/2051-1426-1-S1-P127 |
| work_keys_str_mv | AT burrishoward aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT ansellstephen aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT neumanitisjohn aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT weissgeoffrey aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT sikicbranimir aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT northfeltdonald aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT piljalana aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT davisthomas aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT yellinmichael aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT kelertibor aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT bullocktimothy aphaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT burrishoward phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT ansellstephen phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT neumanitisjohn phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT weissgeoffrey phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT sikicbranimir phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT northfeltdonald phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT piljalana phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT davisthomas phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT yellinmichael phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT kelertibor phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors AT bullocktimothy phaseistudyofanagonistanticd27humanantibodycdx1127inpatientswithadvancedhematologicmalignanciesorsolidtumors |